A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus RCHOP in Previously Untreated, High-intermediate

Grants and Contracts Details

StatusActive
Effective start/end date9/29/218/21/23

Funding

  • MorphoSys AG: $19,444.00